炎症性肠病相关的代谢通路扰动及其药物研发

Metabolic Disturbances in Inflammatory Bowel Disease and Metabolomics-based Drug Developments

炎症性肠病(IBD)是一种可侵犯全消化道并伴有免疫异常的全身性疾病,发病机制未明,发病率逐年上升。目前,IBD治疗药物存在特异性不强、不良反应多等问题,亟待开展新型IBD治疗药物的基础与应用研究。代谢组学可表征机体中内源性小分子代谢物的种类和浓度在受到疾病扰动或药物干预时的整体和动态变化,有助于对疾病机制或药物作用机制的系统研究和全面阐释。IBD可引起体内代谢调控异常,综述近年来基于代谢组学技术开展IBD相关研究的进展,重点对代谢组学揭示的若干受到扰动的代谢通路进行整理,希望有助于全面深入探究IBD的发病机制,并为开展相关药物研发提供有益参考。

Inflammatory bowel disease （IBD） is a systemic disease that affects the whole digestive tract and is associated with immune abnormalities. However, the pathogenesis of IBD remains unclear and the incidence rate is increasing. Currently available drugs for IBD suffer from low selectivity and various adverse reactions, leading to the urgency to investigate and develop new IBD therapy. Metabolomics characterizes the overall and dynamic changes of endogenous small molecule metabolites in biological systems in response to pathophysiological stimuli or genetic modification, which helps with systematic investigation and elucidation of diseases pathogenesis and mechanisms of action of new drugs. Since IBD is found to cause metabolic disorders, the latest progress in metabolomics-based IBD research is briefly introduced in this review with special focus on the disrupted metabolic pathways revealed by metabolomics, so as to help with further exploration oflBD pathogenesis and provide reference for related drug developments.